Phase 3 Clinical Trial Results on J&J’s COVID-19 Vaccine to Be Released Soon

Johnson & Johnson (J&J) may publish data from its COVID-19 vaccine’s Phase 3 clinical trial as early as the end of January. The 45,000 subject study began on December 17, 2020. If the results demonstrate the vaccine’s safety and efficacy, it could receive Emergency Use Authorization (EUA) from the United States Food and Drug Administration by February. The American pharmaceutical giant is prepared to provide the US with 100 million doses as soon as the EUA is granted.

The release of the J&J vaccine could be a game changer as the nation struggles to address rising COVID-19 cases because it only requires one shot to achieve immunity and does not necessitate subzero storage. The J&J vaccine is based on the carrying of a gene from the novel coronavirus—via an adenovirus—into human cells. This creates coronavirus proteins, which should elicit an immune response. Click here to read more.